Standard BioTools

Name

Standard BioTools

Legal name

Standard BioTools Inc.

Website

https://standardbio.com

Company type

Public

Founded year

1999

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Standard BioTools (NASDAQ: LAB) designs mass cytometry, Imaging Mass Cytometry, and microfluidic genomics instruments, consumables, and lab services for pharma, biotech, academic, clinical, and agrigenomics customers globally, and is merging with Treeline Biosciences in 2026.

Ownership category

akta.pro rank

Product category

Life Sciences Instruments

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071)

akta.pro primary industry

Mass Spectrometry & Spectroscopy Instruments (HLAGAIAB)

akta.pro secondary industries

Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF)

Keywords

• Mass cytometry instruments
• Microfluidics genomics systems
• Imaging mass cytometry
• Spatial proteomics platforms
• Single-cell proteomics

Headquarters

HQ city

South San Francisco

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Instruments: Sale of capital equipment including CyTOF systems, Hyperion imaging systems, and Biomark genomics systems. These are high-value instruments with typical enterprise sales cycles.
2. Consumables: Recurring revenue from antibodies, reagents, IFC chips, panels, and assay kits. Q1 2026 showed 35% growth in consumables revenue, indicating strong recurring revenue base.
3. Lab Services: Fee-for-service laboratory work where Standard BioTools runs samples for customers using their platforms, providing data as a service offering.
4. Licensing Royalties: 2% royalty on SOMAmer-based NGS library preparation kit revenues for 10 years retained from the SomaLogic sale to Illumina, plus co-exclusive license to Single SOMAmer IP.
5. Earnout Payments: Up to $75 million in additional earnout payments tied to 2025 and 2026 performance targets from the SomaLogic sale.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

Standard BioTools designs, manufactures, and sells precision life sciences instruments and consumables for multi-omics research. Its core platform comprises three proprietary instrument systems—the CyTOF XT PRO mass cytometer for single-cell proteomics, the Biomark X9 System for high-throughput microfluidics-based genomics (PCR, qPCR, NGS library prep), and the Hyperion XTi Imaging System for Imaging Mass Cytometry spatial proteomics—supported by a consumables catalog of metal-labeled Maxpar antibodies, Integrated Fluidic Circuits, custom reagents, and a Lab Services offering that runs customer samples on its platforms.

Product overview

Standard BioTools is a life sciences tools company providing precision genomic and proteomic solutions through a platform-plus-modules architecture. The core portfolio centers on three instrument systems: the Biomark X9 System for high-throughput microfluidics-based genomics (real-time PCR and NGS library prep), the CyTOF XT PRO system for mass cytometry-based single-cell proteomics, and the Hyperion XTi Imaging System for Imaging Mass Cytometry spatial proteomics. These platforms are complemented by an extensive consumables ecosystem including Maxpar metal-labeled antibodies (800+ catalog items), Integrated Fluidic Circuits (IFCs), and specialized panels such as the Maxpar Direct Immune Profiling Assay and LyoMax lyophilized panels. Software tools including CyTOF Panel Designer, MCD Viewer, and analysis software support instrument operation and data workflows. Services include custom antibody conjugation, D3 genomic assay design, and laboratory services. The company historically operated the SomaScan proteomics platform through its SomaLogic subsidiary, which was sold to Illumina in January 2026.

Differentiator

Problem solved

Functional benefit

Brands

• CyTOF: Mass cytometry technology platform for single-cell proteomics analysis
• Hyperion
• Biomark
• Maxpar
• Advanta
• SomaScan

Products and services

• Biomark X9 System High-throughput genomics platform for real-time PCR and next-generation sequencing library preparation using microfluidics-based integrated fluidic circuits (IFCs). The only automated walk-away PCR/qPCR/NGS library prep system on the market, enabling up to 9,216 reactions per run with minimal sample and reagent consumption and 96x less reagents compared to plate-based methods.
• CyTOF XT PRO system Advanced mass cytometry system for single-cell proteomics that analyzes immune responses at scale, capturing 50+ targets simultaneously including cell surface markers, signaling proteins, and cytokines with 21 CFR Part 11 compliance for clinical research. Designed for clinical trials with enhanced barcoding capabilities.
• Hyperion XTi Imaging System Imaging Mass Cytometry system for spatial proteomics that enables simultaneous analysis of 40+ protein and RNA markers on tissue sections at subcellular resolution with three imaging modes (Preview, Cell, Tissue) and automated slide loading for whole slide imaging.
• Lab Services Multi-omic services turning samples into high-quality data, including multiplexed tissue imaging with Hyperion XTi, single-cell analysis with CyTOF technology, and spatial proteomics with expert scientific team support. Lab Services support research at all top 20 pharmaceutical companies and operate globally with labs in Canada, Asia, and the US.
• Integrated Fluidic Circuits (IFCs) Precision-manufactured microfluidic chips including Flex Six, 48.48, 96.96, and 192.24 formats that automate molecular biology reactions in nanoliter volumes for various genomic applications. Consumables for the Biomark X9 and related genomics platforms.
• Maxpar Antibodies Catalog of over 800 metal-labeled antibodies detecting more than 400 unique human or mouse targets including cell-surface targets, cytokines, signaling proteins, and transcription factors for mass cytometry applications. Available via the Standard BioTools online catalog.
• Maxpar Antibody Conjugation Service Custom conjugation service that expands CyTOF panels by adding metal-labeled targets using 51 high-purity metal tags, with optional biochemical or biological confirmation testing for customer-specific research needs.
• D3 Assay Design Expert-guided custom genomic panel design service supporting SNP Type genotyping assays, Delta Gene expression assays, and targeted NGS assays with two-week average delivery time.
• Single SOMAmer Reagents Proprietary SOMAmer (Slow Off-rate Modified Aptamer) reagents enabling proteomics analysis. Standard BioTools retained rights to single SOMAmer commercialization following the January 2026 sale of SomaLogic to Illumina, maintaining capabilities in protein detection and analysis.

Quantifiable outcome

• Up to 135 cell surface and intracellular antigens can be quantified simultaneously
• +7 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Treeline BiosciencescoreStrategic or Co-development Partner · 8 June 2026Reverse merger transaction valued at approximately $900 million, transforming Standard BioTools from a life sciences tools company into a clinical-stage biotechnology business. Combined entity will have over $900M in cash and be led by Treeline CEO Josh Bilenker. Expected to close H2 2026.
• Indiana University Genetics BiobankminorStrategic or Co-development Partner · 23 December 2025Partnership for SNP-based genetic fingerprinting workflows supporting sample identity and quality control in biobanking. The IUGB, with approximately 4.5 million specimens, utilizes Standard BioTools microfluidics platforms for DNA fingerprinting workflows to verify sample identity.
• Molecular InstrumentscoreStrategic or Co-development Partner · 19 November 2025Collaboration to develop advanced Imaging Mass Cytometry workflows incorporating HCR (Hybridization Chain Reaction) imaging technologies. The integration aims to improve sensitivity and flexibility by enabling amplified detection of RNA and protein markers, facilitating multi-omic analysis within a single workflow using the Hyperion Imaging System.
• Genomics EnglandcoreStrategic or Co-development Partner · 10 November 2025Collaboration with Illumina's Protein Prep solution for proteomics research supporting Genomics England's population health initiatives.
• Precision Health Research, Singapore (PRECISE-SG100K)coreStrategic or Co-development Partner · 10 August 2025Collaboration using SomaScan platform for large-scale population health study analyzing 100,000 samples. Represents Singapore's national effort to advance precision medicine through comprehensive proteomics profiling.
• IlluminacoreTechnology or Integration · 23 June 2025Sale of SomaLogic subsidiary for $350M upfront plus up to $75M earnout. Standard BioTools retains 2% royalty on SOMAmer-based NGS library preparation kits for 10 years and co-exclusive license to Single SOMAmer IP. Post-sale, Illumina integrates SomaScan proteomics into its multiomics platform.

Scale indicators18 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Cytek Biosciences: Spectral flow cytometry competitor offering high-parameter cell analysis instruments (Aurora, Northern Lights). Direct competitor to CyTOF in single-cell proteomics workflows serving pharma, academic and clinical research customers.
• 10x Genomics: Single-cell and spatial biology platform (Chromium, Visium/Xenium) competing head-to-head with Standard BioTools' Biomark and Hyperion products in multi-omics and spatial biology research markets.
• Akoya Biosciences: Spatial biology company with CODEX and PhenoCycler platforms that compete with Hyperion XTi in multiplexed tissue imaging for immuno-oncology and translational research applications.

Broad incumbents

• Becton, Dickinson and Company (BD): Life sciences tools incumbent with the BD FACSDiscover and broader flow cytometry portfolio. Competes with CyTOF in cell analysis and has a much larger installed base across pharma and academic labs.
• Bio-Rad Laboratories: Established life science tools company with the ZE5 cell analyzer and Bio-Plex multiplexed assay platforms. Competes with both Standard BioTools' flow/mass cytometry and genomics product lines.
• Thermo Fisher Scientific: Diversified life sciences tools giant offering flow cytometers, mass spectrometers and genomics instruments that overlap with CyTOF, Hyperion and Biomark, particularly through its specialty diagnostics and PPD clinical research services.
• Danaher (Beckman Coulter Life Sciences / Cytiva): Multi-platform life sciences conglomerate whose Beckman Coulter flow cytometry and Cytiva bioprocessing portfolios compete with Standard BioTools in research and translational lab markets.

Emerging players

• Mission Bio: Single-cell multi-omics company (Tapestri) focused on genomics + proteomics at single-cell resolution. Competes with CyTOF and Biomark for translational and clinical genomics research budget.
• Bruker Corporation: Mass spectrometry and analytical instruments vendor offering timsTOF and related cytometry-adjacent platforms that compete with CyTOF mass cytometry in proteomics research.

Others

• Illumina: Sequencing giant that acquired SomaLogic from Standard BioTools and now sells the Protein Prep solution, including the 40+ institutions Standard BioTools formerly served. Strategic counterparty and genomics ecosystem partner rather than a direct CyTOF competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/fluidigm
• Facebookfacebook.com/Fluidigm
• LinkedInlinkedin.com/company/fluidigm-corporation

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries2 records

Funding overview

Funding rounds9 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Standard BioTools